The application of gene therapy in China

Abstract

Since the 1990s, gene therapy has been broadly applied in the treatment of life-threatening diseases, including infectious disease, cancer, cardiovascular disease and hereditary diseases. China in particular has become a competitive marketplace for the development of biotechnology and gene therapy products. This article provides an overview of the regulatory guidance for gene therapy research, product development and commercialization in China. The first approved gene therapy product, recombinant human adenoviral p53 injection (Gendicine), is highlighted as an example of the innovation occurring in the field in China.